Source: http://globenewswire.com/
MENLO PARK, Calif., March 29, 2016 (GLOBE NEWSWIRE) -- Corium International, Inc. (Nasdaq:CORI), a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal products, today announced the publication of a paper in the Early Edition of the Proceedings of the National Academy of Sciences (PNAS), titled “Long-acting Potent GLP-1 Analog Delivered in Microstructure-based Transdermal Patch”. The results demonstrate that the combination of MicroCor transdermal system with E6, a new GLP-1R agonist, resulted in improved peptide effectiveness by increasing plasma stability and providing sustained glucose control in a preclinical proof-of-concept study.
The research was conducted in partnership with the California Institute for Biomedical Research (Calibr) and the Scripps Research Institute (TSRI). In the study, E6, which was developed using a novel peptide engineering strategy, was formulated in Corium’s dissolving microstructure transdermal delivery system. A single five-minute application of the MicroCor system resulted in bioavailability comparable to subcutaneous injection, with corresponding improvements in glucose tolerance sustained for up to four days.
The MicroCor transdermal delivery approach has the potential to offer a safe, effective, convenient and needle-free alternative to currently marketed GLP-1 injectables for the treatment of diabetes and obesity. The MicroCor system has been clinically validated with parathyroid hormone, and the results published today with GLP-1 continue to support broader applications, including other therapeutic peptides and proteins, and vaccines.
Read more: http://globenewswire.com/news-release/2016/03/29/823807/0/en/Corium-Announces-Positive-Preclinical-Results-with-Long-acting-Potent-GLP-1-Analog-Delivered-in-MicroCor-Transdermal-Patch.html?f=22&fvtc=7